Fibrocell Science (FCSC), an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints.
FCSC’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
FCSC has a collaboration agreement with Intrexon Corporation (XON)for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.
The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009; was incorporated in 1992 and is based in Exton, Pennsylvania.
December 24, 2020
Happy Hanukkah and a Merry Christmas as the NEW Year 2021 approaches
April 30, 2018
RegMed Investors’ (RMi) closing bell; finally April is over
April 24, 2018
RegMed Investors’ (RMi) closing bell; an embattled sector
April 13, 2018
RegMed Investors’ (RMi) closing bell; the sector slipped
35 companies, 1 interpreter!
Insight, foresight and recommendation
Fibrocell Science (FCSC) has always been (to me) a disappointment. January '18 opened at $0.69, rolled barely up and slightly down to open 2/1 at $0.66 and sliding into second base at $0.67 on 2/16 ...Still early with a submission of an IND Application with the U.S. FDA for FCX-013, the Company’s gene therapy candidate for the treatment of moderate to severe localized scleroderma.hold
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors